NDA 016931 · Pharmacia and Upjohn
R-Gene 10
Arginine Hydrochloride · Injection
Priority reviewLast checked: Nov 20, 2026Latest source record: Jan 17, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1973
Feb 28, 1973
Approved uses
1
Original approval plus efficacy supplements
Registered trials
459
88 Phase 3, 51 recruiting
FAERS reports
103
83 serious, 8 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 2, 2024.
INDICATIONS AND USAGE R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 28, 1973 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
1 products under this application
- R-GENE 10 · ARGININE HYDROCHLORIDE 10GM/100ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Arginine" as an intervention, any sponsor and status, largest first.
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)Pivotal-lookingCompleted
Hospital Israelita Albert EinsteinAcademic, hospital or other
NCT04040634 · 9,476 participants · Start Aug 8, 2019 · Primary completion Jul 8, 2026
Drug: Intensive Control of Systolic Blood Pressure (SBP); Standard control of Systolic Blood Pressure (SBP) · For: Diabetes Mellitus; High Blood Pressure; Cardiovascular Diseases and 1 more
Sites: Maceió, Brazil; Fortaleza, Brazil; Vitória, Brazil · 32 sites in all
- 2-year Caries Clinical Study: Arginine Fluoride-Free Toothpastes vs. NaF ToothpastePivotal-lookingCompleted
Colgate PalmoliveIndustry
NCT05560945 · 6,000 participants · Start Apr 15, 2019 · Primary completion Mar 12, 2022
Drug: 0.32% Sodium Fluoride Dentifrice Toothpaste; 1.5% Arginine Dentifrice and 1 more · For: Dental Caries
Sites: Xi'an, China; Chengdu, China; Chongqing, China
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke PatientsPivotal-lookingCompleted
Hospital Israelita Albert EinsteinAcademic, hospital or other
NCT04036409 · 4,368 participants · Start Aug 5, 2019 · Primary completion Jul 8, 2026
Drug: Intensive Control of Systolic Blood Pressure (SBP); Standard control of Systolic Blood Pressure (SBP) · For: Ischemic Stroke; Blood Pressure; Cognitive Impairment and 1 more
Sites: Rio Branco, Brazil; Maceió, Brazil; Botucatu, Brazil · 30 sites in all
- Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac ArrestPivotal-lookingCompleted
Hospices Civils de LyonAcademic, hospital or other
NCT00127907 · 2,416 participants · Start May 2, 2004 · Primary completion Oct 1, 2007
Drug: epinephrine (1 mg/1 mL); arginine-vasopressin (40 UI/2 mL) · For: Cardiac Arrest
Sites: Pierre-Bénite, France
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldPivotal-lookingStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05015686 · 2,400 participants (planned) · Start Sep 30, 2021 · Primary completion Feb 9, 2022
Drug: Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd; Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd and 2 more · For: Varicella
Sites: Shangqiu, China
- A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old ChildrenPivotal-lookingCompleted
Colgate PalmoliveIndustry
NCT04750902 · 2,025 participants · Start Jan 21, 2021 · Primary completion Feb 28, 2024
Drug: 0.24% Sodium Fluoride Dentifrice; 1.5% Arginine Dentifrice and 2 more · For: Dental Caries
Sites: Loma Linda, California; Gainesville, Florida; Indianapolis, Indiana · 9 sites in all
- Perindopril Amlodipine for the Treatment of HypertensionPivotal-lookingCompleted
Symplmed Pharmaceuticals LLCIndustry
NCT01556997 · 837 participants · Start Feb 2012 · Primary completion Feb 2013
Drug: XOMA 985; Amlodipine Besylate and 1 more · For: Essential Hypertension
Sites: Huntsville, Alabama; Muscle Shoals, Alabama; Glendale, Arizona · 48 sites in all
- Efficacy and Safety of Desmopressin Melt for the Treatment of NocturiaPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00477490 · 799 participants · Start May 2007 · Primary completion Feb 2008
Drug: desmopressin acetate; Placebo · For: Nocturia
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 80 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypotension10
- off label use8
- haematuria7
- vomiting7
- diarrhoea6
- nausea6
- cardiac disorder5
- drug ineffective5
- fatigue5
- malaise5
- atrial fibrillation4
- cough4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 10 |
| 2011 | 3 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 7 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 8 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 13 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of food sources of nitrate, polyphenols, L-arginine and L-citrulline on endurance exercise performance: a systematic review and meta-analysis of randomised controlled trials.
d'Unienville NMA, Blake HT, Coates AM, et al. · J Int Soc Sports Nutr 2021 · Meta-Analysis, Systematic Review
- The Effect of Amino Acids on Wound Healing: A Systematic Review and Meta-Analysis on Arginine and Glutamine.
Arribas-López E, Zand N, Ojo O, et al. · Nutrients 2021 · Meta-Analysis, Systematic Review
- The Potential Role of Arginine Supplements on Erectile Dysfunction: A Systemic Review and Meta-Analysis.
Rhim HC, Kim MS, Park YJ, et al. · J Sex Med 2019 · Meta-Analysis, Systematic Review
- Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency.
Refardt J, Atila C, Chifu I, et al. · N Engl J Med 2023 · Equivalence Trial, Research Support, Non-U.S. Gov't
- Efficacy of L-arginine and Pycnogenol ® in the treatment of male erectile dysfunction: a systematic review and meta-analysis.
Tian Y, Zhou Q, Li W, et al. · Front Endocrinol (Lausanne) 2023 · Meta-Analysis, Systematic Review
- Comparative Effects of Different Nutritional Supplements on Inflammation, Nutritional Status, and Clinical Outcomes in Colorectal Cancer Patients: A Systematic Review and Network Meta-Analysis.
Ye J, Hu Y, Chen X, et al. · Nutrients 2023 · Systematic Review, Network Meta-Analysis
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.